Recent advances in CAR-T cell engineering

Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for relapsed or refractory tumors, particularly for hematological malignancies. Although the initially approved anti-CD19 CAR-T therapy has produced impressive outcomes, setbacks such as high relapse rates and resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ruihao, Li, Xiaoping, He, Yundi, Zhu, Wen, Gao, Lei, Liu, Yao, Gao, Li, Wen, Qin, Zhong, Jiang F., Zhang, Cheng, Zhang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333410/
https://www.ncbi.nlm.nih.gov/pubmed/32616000
http://dx.doi.org/10.1186/s13045-020-00910-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333410/
https://www.ncbi.nlm.nih.gov/pubmed/32616000
http://dx.doi.org/10.1186/s13045-020-00910-5

Ejemplares similares